

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF NEW JERSEY**

-----  
IN RE: JOHNSON & JOHNSON TALCUM : Civil Action No. 3:16-md-2738-FLW-LHG  
POWDER PRODUCTS MARKETING, :  
SALES PRACTICES AND PRODUCTS :  
LIABILITY LITIGATION : MDL No. 2738  
:  
:  
:  
:  
:  
:  
-----

---

**DEFENDANT IMERYS TALC AMERICA, INC. F/K/A LUZENAC AMERICA, INC.'S  
RESPONSE TO PLAINTIFFS' STEERING COMMITTEE'S OBJECTION TO MAY 23,  
2018 CASE MANAGEMENT ORDER OF THE SPECIAL MASTER RELATING TO  
30(B)(6) DEPOSITIONS**

---

**COUGHLIN DUFFY LLP**  
350 Mount Kemble Avenue  
Morristown, New Jersey 07962  
(973) 267-0058

**GORDON & REES SCULLY  
MANSUKHANI**  
121 SW Morrison Street, Ste. 1575  
Portland, OR 97204

Defendant Imerys Talc America, Inc. (“Imerys”) submits this response to the PSC’s Objection to the May 23, 2018 Case Management Order of the Special Master Relating To 30(B)(6) Depositions. Although the original issue was brought before Special Master Pisano by co-defendant Johnson & Johnson, Imerys hereby submits the following response due to the fact that: 1) the ruling equally applies to the scope of Imerys’ 30(b)(6) witness depositions; and 2) the basis for the PSC’s objection is largely based on Imerys’ discovery of and disclosure of additional samples.

In addition to the arguments below, Imerys hereby adopts and incorporates the arguments set forth in J&J’s response to the PSC’s Objection to the May 23, 2018 Case Management Order of the Special Master Relating To 30(B)(6) Depositions. All of J&J’s arguments regarding the PSC’s efforts to create a discovery sideshow are equally applicable to Imerys.

The PSC’s entire argument is a red herring designed to: 1) further delay issuing its expert reports on general causation; and 2) obfuscate the line between causation issues and liability issues. The requested 30(b)(6) inquiries regarding samples have little to do with science. The only possible objective of the requested inquiry is for the PSC to attempt to build a discovery dispute and further sidetrack this litigation.

First, as a procedural matter, the PSC is attempting to use Imerys’ supplemental sample disclosure as some sort of “gotcha” moment. The actual facts are much simpler than that and not at all nefarious. Imerys previously identified and produced the relevant samples of which it was aware. As discovery (and trials) progressed in other jurisdictions, additional samples not previously identified were located. Pursuant to the Federal Rules of Civil Procedure and the applicable Case Management Orders in this matter, Imerys believed that it was obligated to identify the newly found samples in this litigation and it did so via its May 30, 2018 letter. As

stated in that letter, Imerys does not even know if some of the talc samples it disclosed are relevant to this litigation. However, in an abundance of caution, and because a similar disclosure was being made in some California state asbestos cases, Imerys chose to be over-inclusive with its supplemental disclosure of the additional samples it had located.

With respect to the “Lanzo Box” that is referenced in the PSC’s submission, the history is as follows: During the trial of Lanzo v. Johnson & Johnson, et al., Julie Pier, an Imerys witness with knowledge regarding Imerys’ samples, was confronted with a 2009 e-mail that referenced a box of historical samples that were sent to storage. Not surprisingly, Ms. Pier did not recall the contents of a single email she had received nine years earlier, nor the samples referenced in it, but she did confirm that the email indicated the existence of a box of samples. Following Ms. Pier’s testimony during the Lanzo trial, Imerys set out to locate what colloquially became referred to as the “Lanzo Box”. The search took longer than expected because, although it was determined that the box had been sent to Iron Mountain for storage, the box had been mislabeled. This led to what can best be described as a search for a needle in a very large haystack. Ultimately, the “Lanzo Box” was located and the contents disclosed. An inventory of the Lanzo Box was sent to the PSC on June 8, 2018.

Those samples (and the others disclosed in the May 31, 2018 letter) have been offered to the PSC for splitting and testing.

However, as Judge Pisano correctly identified, the PSC’s interest in Imerys’ samples, or more correctly stated for this appeal, “lost” or “missing samples,” has nothing to do with science, general causation, and/or any of the issues to be decided by the Court in a Daubert hearing. Despite the PSC’s protestations to the contrary, analysis of Imerys samples (existing or no longer preserved), will not assist this Court in answering the question: Do J&J body powders cause

ovarian cancer? The reason Imerys can make this statement with such certainty is that Imerys' samples are not samples of the product that were utilized by the Plaintiffs. At best, Imerys' samples are only representative of the raw unfinished product that was shipped to Johnson & Johnson.

Plaintiffs already have access to more samples than they will ever test. As the PSC has stated to this Court on several occasions, the question before this Court is whether talc causes ovarian cancer. Pursuing isolated samples is not going assist the Court with that ultimate issue. Therefore, questions directed to a 30(b)(6) witness regarding samples that Imerys may have had and did not keep do not shed light on the questions of general causation or "influencing of the science."

The best example of this point is the PSC's response to Imerys' supplement sample disclosure. The PSC has been aware of the existence of these additional samples for almost two weeks now. Instead of contacting Imerys to set up splits of these additional samples so that the case can keep moving forward, its inquiries focused on the following questions:

When were these samples discovered?

Who is the custodian?

Why were they not previously disclosed?

*See* the PSC's June 4, 2018 letter to Imerys attached hereto at Exhibit A.

None of those questions are designed to get to a "science related" or "causation" related inquiry. They are all designed to distract the parties and the Court from the real issues in the litigation. Imerys has complied with the applicable Federal Rules and Court Orders at every step in this litigation, making such this line of inquiry all the more inappropriate.

For all of the foregoing reasons, Imerys respectfully requests that the Court uphold the Special Master's rulings on these issues.

Respectfully submitted,

COUGHLIN DUFFY LLP

/s/ Mark K. Silver

Mark K. Silver

Nancy M. Erfle, Esq.

Ann Field, Esq.

Gordon & Rees Scully Mansukhani

121 SW Morrison Street, Ste. 1575

Portland, OR 97204

# EXHIBIT A



**Montgomery**  
218 Commerce Street  
P.O. Box 4160  
Montgomery, AL 36103-4160

**Atlanta**  
4200 Northside Parkway  
Building One, Suite 100  
Atlanta, GA 30327

(800) 898-2034

BeasleyAllen.com

**P. Leigh O'Dell**  
leigh.odell@beasleyallen.com

June 4, 2018

**VIA Electronic Mail**

Mark K. Silver, Esq.  
Coughlin Duffy  
350 Mount Kemble Avenue  
P.O. Box 1917  
Morristown, New Jersey 07962

**Re: *In Re: Johnson & Johnson Talcum Powder Products Marketing, Sales  
Practices and Products Liability Litigation*  
MDL No. 2738**

Dear Mark:

Thank you for your letter of May 30, 2018, disclosing additional Imerys talc samples beyond those that were previously identified in the Agreed Upon Order and Stipulation Regarding the Production of Talc Samples by Imerys Talc America, Inc. (Doc. 4757). This new and unanticipated Imerys disclosure is extensive and implicates samples from every decade since the 1960's.

While the PSC appreciates Imerys's disclosure, I am sure that you must recognize that it raises some troubling questions. These questions include issues about the adequacy of Imerys's prior disclosures, the timing of Imerys's ongoing investigations and, equally important, whether the passage of time will reveal yet more previously undisclosed samples. This new disclosure could not come at a more sensitive time since the sample testing process has begun in earnest and the PSC is operating under an aggressive schedule that was urged by the Defendants and countenanced by the Court. The proposed schedule for testing was based on an obviously erroneous assumption that all available Imerys samples had been disclosed to the PSC.

To determine the ramifications that Imerys's late disclosure might have on the current testing schedule, the PSC requests a call no later than Thursday, June 7.

In anticipation of our discussion, we want to make clear that we believe that we are entitled to the additional information described below to determine not only what additional samples to test but realistically how much time will be necessary to accomplish the testing of those samples. Therefore, we ask that you provide the following information:

Mark Silver, Esq.

June 4, 2018

Page 2 of 3

1. **Samples from 2012-2014:** On page 2 of your letter, you describe 20 additional samples from 2012-2014. Your two-sentence description of these samples leaves many questions unanswered. We need to know when these samples were discovered, where they were located, the custodian of the samples, why they were not identified previously, and whether any additional samples might be maintained in the same or a similar location. Please identify all documents that describe these samples and any prior testing that relates to them (whether performed by Imerys or an outside lab).
2. **“Lanzo Trial Box”:** In a single brief paragraph on page 2 of your letter, you also describe locating a box containing samples of Windsor Grade 66 talc from a 25-year period, 1964-1987. The “box” was first identified by Ms. Julie Pier in the Lanzo trial. We need more information on the “Lanzo Box.” While we understand that you are still preparing an inventory of this box, we need you to describe everything you currently know about it and the samples contained therein. Specifically, we need to know where the box was found, why it was not identified earlier, the custodian of the box, the number of samples in the box, the year that each sample was taken, whether the samples have been tested (by Imerys or by an outside lab), and the identify of any documents related to the samples (including test results). In addition, we need to know when you expect the inventory of this box to be complete so we can make an informed decision on additional samples to test.
3. **Samples Being Identified in Asbestos Litigation:** On page 2 of your letter, you describe 4 additional boxes of samples that have been identified in connection with unspecified “asbestos litigation being litigated throughout the country.” You further state that Imerys is investigating whether these samples are samples of talc sold to J&J. We need much more information about the “Asbestos litigation” boxes. Specifically, we need to know which asbestos cases these samples were identified in, when they were identified, who the defendants are in those cases, whether any of the samples have been tested by Imerys or an outside lab, and the identify of any documents related to these samples (including test results). We need to know if any portion of these samples has been provided to plaintiffs’ counsel for testing. In addition, we are entitled to know when these samples were discovered by Imerys, where these boxes were stored at the time they were discovered, the custodian of the boxes, and why they were not disclosed in the Talc MDL samples protocol. We ask that you to identify each sample by sample number, the year the sample was taken, and any other information available regarding the sample. Lastly, please advise us as to when your investigation and the inventory will be complete.
4. **Samples A05033 and A05075:** On page 3 of your letter, you indicate that Imerys is investigating samples A05033 and A05075. Please tell us when this investigation will be complete.
5. **TEM Grids and Drilling Cores:** As you know, we have been discussing these items for quite some time. Please let us know this week whether you will voluntary provide the TEM grids and drill cores for inspection and/or testing. If not, we need to raise this with the Court as we do not think the Court will want this issue to drift any further into the summer.



Mark Silver, Esq.

June 4, 2018

Page 3 of 3

- 6. Other Potentially Available Samples:** Your letter obviously raises the prospect that even more talc samples may yet be discovered and disclosed. In this regard, we ask that you indicate whether Imerys or its counsel have located any additional samples that they are investigating but which are not described in your May 30<sup>th</sup> letter.

The answer to these questions are time-sensitive. At Defendants' urging, the Court has pressed the PSC to complete its testing at the earliest possible time. In fact, the Court has asked the PSC to report back during the next status conference as to whether sample testing can be completed even earlier than the September 15<sup>th</sup> time frame discussed during the May 8<sup>th</sup> conference. In order to accurately respond to the Court's inquiry, we must know now when your investigation will be completed and, even more importantly, understand just how confident you are that Imerys has finally identified and disclosed to the PSC all potentially relevant samples to the PSC.

Over the past year, the inventory of samples and the protocol for testing has been front-and-center for both the PSC and the Court. The need for an accurate and reliable accounting of available samples is and has been obvious. This new disclosure – of potentially hundreds of newly disclosed samples covering a period of nearly 60 years, years relevant to our clients' use of talcum powder products – has material implications to the PSC's testing of samples and the preparation of its general causation expert reports. Due to the importance of this matter and the seriousness of Imerys's delay in making this important evidence available to the PSC, we trust that Imerys will be forthcoming with all of the information that it has in relation to these samples. We also want to make clear that the PSC reserves the right to take a 30(b)(6) deposition on this issue

We look forward to speaking to you this week.

Best Regards,

*/s/ P. Leigh O'Dell*

P. Leigh O'Dell  
Michelle A. Parfitt

cc: Susan Sharko, Esq. (via e-mail)  
Tom Locke, Esq. (via e-mail)  
Chris Placitella, Esq. (via e-mail)  
Warren Burns, Esq. (via e-mail)  
Richard Golomb, Esq. (via e-mail)  
Richard Meadow, Esq. (via e-mail)  
Hunter Shkolnik, Esq. (via e-mail)  
Christopher V. Tisi, Esq. (via e-mail)  
Larry Berman, Esq. (via e-mail)  
Dan Lapinski, Esq. (via e-mail)